Print

Featured Studies Results

A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone or Darolutamide (TALENT)

https://www.facingourrisk.org/research-clinical-trials/study/425 /a-study-of-talazoparib-with-or-without-enzalutamide-in-people-with-prostate-cancer-who-have-previously-received-abiraterone-or-darolutamide-talent

Clinicaltrials.gov identifier:
NCT06844383 (https://clinicaltrials.gov/show/NCT06844383)

Treatment
Phase 2 study for metastatic castration-resistant prostate cancer with an HRR mutation

Testing COM701 Maintenance Treatment to Delay Cancer Growth After Platinum Chemotherapy for Ovarian Cancer That Has Come Back

https://www.facingourrisk.org/research-clinical-trials/study/381 /testing-com701-maintenance-treatment-to-delay-cancer-growth-after-platinum-chemotherapy-for-ovarian-cancer-that-has-come-back

Clinicaltrials.gov identifier:
NCT06888921 (https://clinicaltrials.gov/show/NCT06888921)

Treatment
Study for relapsed platinum-sensitive ovarian cancer

FIT Testing for Colorectal Cancer Screening in People with Lynch Syndrome

https://www.facingourrisk.org/research-clinical-trials/study/418 /fit-testing-for-colorectal-cancer-screening-in-people-with-lynch-syndrome

Clinicaltrials.gov identifier:
NCT06898996 (https://clinicaltrials.gov/show/NCT06898996)

Prevention
Colon cancer screening study for people with Lynch syndrome

A Study to Learn About the Study Medicine Called PF-07248144 in Combination with Fulvestrant in People with HR-positive, HER2-negative Advanced or Metastatic Breast Cancer who Progressed After a Prior Line of Treatment

https://www.facingourrisk.org/research-clinical-trials/study/414 /a-study-to-learn-about-the-study-medicine-called-pf-07248144-in-combination-with-fulvestrant-in-people-with-hr-positive-her2-negative-advanced-or-metastatic-breast-cancer-who-progressed-after-a-prior-line-of-treatment

Clinicaltrials.gov identifier:
NCT07062965 (https://clinicaltrials.gov/show/NCT07062965)

Treatment
Phase 3 study for adults with advanced/metastatic HR-positive, HER2-negative breast cancer who have progressed from prior treatment

A New Drug, DT2216, Combined With Paclitaxel for Recurrent Platinum-Resistant Ovarian Cancer

https://www.facingourrisk.org/research-clinical-trials/study/429 /a-new-drug-dt2216-combined-with-paclitaxel-for-recurrent-platinum-resistant-ovarian-cancer

Clinicaltrials.gov identifier:
NCT06964009 (https://clinicaltrials.gov/show/NCT06964009)

Treatment
Phase 1b study for people with recurrent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer

Research Study on the Genetics of Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/317 /research-study-on-the-genetics-of-breast-cancer

Clinicaltrials.gov identifier:
NCT06773897 (https://clinicaltrials.gov/show/NCT06773897)

Surveys, Registries, Interviews
A registry for anyone aged 18 and older who lives in the United States

ShareForCures®: Susan G. Komen's People-Powered, Data-Driven Breast Cancer Research Registry

https://www.facingourrisk.org/research-clinical-trials/study/295 /shareforcures-susan-g-komens-people-powered-data-driven-breast-cancer-research-registry

Clinicaltrials.gov identifier:
NCT05654246 (https://clinicaltrials.gov/show/NCT05654246)

Surveys, Registries, Interviews
Registry for anyone diagnosed with breast cancer

IGNITE-TX - Identifying Individuals for Genetic Testing for Familial Cancer

https://www.facingourrisk.org/research-clinical-trials/study/266 /helping-people-with-a-genetic-mutation-in-brca1-brca2-or-lynch-syndrome-talk-to-their-family-members-about-their-risk-for-cancer-and-find-the-best-way-to-get-family-members-tested

Clinicaltrials.gov identifier:
NCT07318363 (https://clinicaltrials.gov/show/NCT07318363)

Prevention
People with a genetic mutation in BRCA1, BRCA2 or Lynch syndrome who have relatives who have not been tested

Previvors’ Perceptions of Preimplantation Genetic Testing (PGT-M) After a Cancer Predisposition Diagnosis

https://www.facingourrisk.org/research-clinical-trials/study/435 /previvors-perceptions-of-preimplantation-genetic-testing-pgt-m-after-a-cancer-predisposition-diagnosis

Surveys, Registries, Interviews
Interview for eligible previvors

Treating Advanced MSI-High or dMMR Cancers Using the Targeted Therapy MOMA-341 Given Alone or In Combination with Standard Therapies

https://www.facingourrisk.org/research-clinical-trials/study/356 /treating-advanced-msi-high-or-dmmr-cancers-using-the-targeted-therapy-moma-341-given-alone-or-in-combination-with-standard-therapies

Clinicaltrials.gov identifier:
NCT06974110 (https://clinicaltrials.gov/show/NCT06974110)

Treatment
Treatment study for people with advanced or metastatic cancers

Understanding Risk Factors for Stomach Cancer in People with Inherited Mutations

https://www.facingourrisk.org/research-clinical-trials/study/332 /understanding-risk-factors-for-stomach-cancer-in-people-with-inherited-mutations

Surveys, Registries, Interviews
Online survey on stomach cancer risk for people with an inherited mutation in genes that are linked to an increased risk of certain cancers

REKINDLE: Your Ability to Cope With a Life-Changing Medical Diagnosis

https://www.facingourrisk.org/research-clinical-trials/study/423 /rekindle-your-ability-to-cope-with-a-life-changing-medical-diagnosis

Clinicaltrials.gov identifier:
NCT07002034 (https://clinicaltrials.gov/show/NCT07002034)

Quality of Life
Study for those experiencing mental health struggles due to a diagnosis of cancer or other medical illness

Multi-Cancer Detection Blood Tests in Adults Without Cancer: Vanguard Study

https://www.facingourrisk.org/research-clinical-trials/study/394 /multi-cancer-detection-blood-tests-in-adults-without-cancer-vanguard-study

Clinicaltrials.gov identifier:
NCT06995898 (https://clinicaltrials.gov/show/NCT06995898)

Prevention
A study testing two multi-cancer detection blood tests in people who do not have cancer

A Study of the Drug Romosozumab in People With Metastatic Breast Cancer and Osteoporosis

https://www.facingourrisk.org/research-clinical-trials/study/433 /a-study-of-the-drug-romosozumab-in-people-with-metastatic-breast-cancer-and-osteoporosis

Clinicaltrials.gov identifier:
NCT07776613 (https://clinicaltrials.gov/show/NCT07776613)

Quality of Life
Phase 2 study for people with metastatic breast cancer and osteoporosis

Family Study for People with Certain Rare BRCA1 or BRCA2 Variants

https://www.facingourrisk.org/research-clinical-trials/study/428 /family-study-for-people-with-certain-rare-brca1-or-brca2-variants

Surveys, Registries, Interviews
Family study for adults with a known rare BRCA1 or BRCA2 variant in themselves or a relative

Psilocybin Therapy in Advanced Cancer

https://www.facingourrisk.org/research-clinical-trials/study/436 /psilocybin-therapy-in-advanced-cancer

Clinicaltrials.gov identifier:
NCT05398484 (https://clinicaltrials.gov/show/NCT05398484)

Quality of Life
Phase 2 study for people with advanced cancer

Please Help us Learn More About Immunotherapy Side Effects That People With Cancer Experience

https://www.facingourrisk.org/research-clinical-trials/study/421 /a-5-minute-patient-and-caregiver-survey-to-share-experiences-with-immunotherapy-and-any-short-term-or-long-term-side-effects

Surveys, Registries, Interviews
This 5-minute survey allows cancer patients on immunotherapy (currently or in the past) and their caregivers to share their experiences, including their side effects and whether they were resolved or not.

A Phase 2 Study of Dostarlimab Immunotherapy in People with Mismatch Repair-Deficient Endometrial Cancer Who Wish to Preserve Fertility

https://www.facingourrisk.org/research-clinical-trials/study/434 /a-phase-ii-study-of-dostarlimab-immunotherapy-in-people-with-mismatch-repair-deficient-endometrial-who-wish-to-preserve-fertility

Clinicaltrials.gov identifier:
NCT04165772 (https://clinicaltrials.gov/show/NCT04165772)

Treatment
Phase 2 treatment study for people with MSI-H or dMMR early-stage endometrial cancer.

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.